Blockchain Registration Transaction Record

Oncotelic & Sapu Bioscience Unveil Breakthrough Nanoparticle Research

Oncotelic Therapeutics and Sapu Bioscience publish groundbreaking nanoparticle research in International Journal of Molecular Sciences, revealing new drug delivery potential for cancer and rare diseases.

This nanoparticle research represents a potential paradigm shift in drug delivery that could significantly improve treatment outcomes for patients with cancer, neurological disorders, and other conditions where conventional therapies struggle with delivery barriers. The ability of sub-15 nm particles to cross the blood-brain barrier opens new possibilities for treating brain tumors and neurological diseases that were previously considered untreatable with systemic medications. For patients, this could mean more effective treatments with fewer side effects, as the targeted delivery reduces accumulation in healthy organs. The faster renal clearance also addresses one of the major safety concerns in nanomedicine, potentially making these therapies safer for long-term use. This advancement could accelerate the development of precision medicines that deliver drugs exactly where needed while minimizing damage to healthy tissues.